Cancer Risks Associated With TP53 Pathogenic Variants : Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum
PURPOSE: Establishing accurate age-related penetrance figures for the broad range of cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 gene is essential to determine the most effective clinical management strategies. These figures also permit optimal use of cosegregation data for classification of TP53 variants of unknown significance. Penetrance estimation can easily be affected by bias from ascertainment criteria, an issue not commonly addressed by previous studies.
MATERIALS AND METHODS: We performed a maximum likelihood penetrance estimation using full pedigree data from a multicenter study of 146 TP53-positive families, incorporating adjustment for the effect of ascertainment and population-specific background cancer risks. The analysis included pedigrees from Australia, Spain, and United States, with phenotypic information for 4,028 individuals.
RESULTS: Core Li-Fraumeni syndrome (LFS) cancers (breast cancer, adrenocortical carcinoma, brain cancer, osteosarcoma, and soft tissue sarcoma) had the highest hazard ratios of all cancers analyzed in this study. The analysis also detected a significantly increased lifetime risk for a range of cancers not previously formally associated with TP53 pathogenic variant status, including colorectal, gastric, lung, pancreatic, and ovarian cancers. The cumulative risk of any cancer type by age 50 years was 92.4% (95% CI, 82.2 to 98.3) for females and 59.7% (95% CI, 39.9 to 81.3) for males. Females had a 63.3% (95% CI, 35.6 to 90.1) cumulative risk of developing breast cancer by age 50 years.
CONCLUSION: The results from maximum likelihood analysis confirm the known high lifetime risk for the core LFS-associated cancer types providing new risk estimates and indicate significantly increased lifetime risks for several additional cancer types. Accurate cancer risk estimates will help refine clinical recommendations for TP53 pathogenic variant carriers and improve TP53 variant classification.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCO precision oncology - 8(2024) vom: 07. Feb., Seite e2300453 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fortuno, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 07.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1200/PO.23.00453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369023250 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369023250 | ||
| 003 | DE-627 | ||
| 005 | 20240307232436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/PO.23.00453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM369023250 | ||
| 035 | |a (NLM)38412388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fortuno, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Risks Associated With TP53 Pathogenic Variants |b Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Establishing accurate age-related penetrance figures for the broad range of cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 gene is essential to determine the most effective clinical management strategies. These figures also permit optimal use of cosegregation data for classification of TP53 variants of unknown significance. Penetrance estimation can easily be affected by bias from ascertainment criteria, an issue not commonly addressed by previous studies | ||
| 520 | |a MATERIALS AND METHODS: We performed a maximum likelihood penetrance estimation using full pedigree data from a multicenter study of 146 TP53-positive families, incorporating adjustment for the effect of ascertainment and population-specific background cancer risks. The analysis included pedigrees from Australia, Spain, and United States, with phenotypic information for 4,028 individuals | ||
| 520 | |a RESULTS: Core Li-Fraumeni syndrome (LFS) cancers (breast cancer, adrenocortical carcinoma, brain cancer, osteosarcoma, and soft tissue sarcoma) had the highest hazard ratios of all cancers analyzed in this study. The analysis also detected a significantly increased lifetime risk for a range of cancers not previously formally associated with TP53 pathogenic variant status, including colorectal, gastric, lung, pancreatic, and ovarian cancers. The cumulative risk of any cancer type by age 50 years was 92.4% (95% CI, 82.2 to 98.3) for females and 59.7% (95% CI, 39.9 to 81.3) for males. Females had a 63.3% (95% CI, 35.6 to 90.1) cumulative risk of developing breast cancer by age 50 years | ||
| 520 | |a CONCLUSION: The results from maximum likelihood analysis confirm the known high lifetime risk for the core LFS-associated cancer types providing new risk estimates and indicate significantly increased lifetime risks for several additional cancer types. Accurate cancer risk estimates will help refine clinical recommendations for TP53 pathogenic variant carriers and improve TP53 variant classification | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 700 | 1 | |a Feng, Bing-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Innella, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Kohlmann, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Lázaro, Conxi |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Feliubadaló, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Menéndez, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Teulé, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Ballinger, Mandy L |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Ainsley |e verfasserin |4 aut | |
| 700 | 1 | |a Field, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Kirk, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Pachter, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Poplawski, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Susman, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Tucker, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Wallis, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Cops, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Goldgar, David |e verfasserin |4 aut | |
| 700 | 0 | |a kConFab Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a James, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Spurdle, Amanda B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d 2017 |g 8(2024) vom: 07. Feb., Seite e2300453 |w (DE-627)NLM273576054 |x 2473-4284 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g day:07 |g month:02 |g pages:e2300453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/PO.23.00453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |b 07 |c 02 |h e2300453 | ||